AI drug-design out-licensing hits $75B in 2026 as US scrutiny tightens

China AI drug-design may sound like a niche tech trend, until you look at the numbers: out-licensing deals struck by Chinese biotech companies with top global multinational pharmaceutical companies hit US$75 billion in the first five months of 2026, according to Linda Shu, head of China healthcare research at HSBC. The scale is hard to miss because it is not just “growth.” It is a rebound from a baseline of zero before 2020.

What that means in plain English is that the global pharma pipeline is increasingly getting fed by Chinese biotech through licensing agreements, and it is happening fast. In the first five months of 2026 alone, the deal value climbed to US$75 billion, reversing the pre-2020 picture when these out-licensing deal values were essentially non-existent. And this surge is happening at the same time Washington scrutiny of Chinese biotech firms is mounting, creating a rare tension: more capital flowing out of China into global partnerships while political and regulatory attention keeps tightening.

To understand why executives should care, start with what out-licensing actually represents for both sides. For global multinational pharma companies, licensing is a way to buy access to drug discovery capabilities, targets, and early-stage programs without building everything internally from scratch. For Chinese biotech firms, out-licensing is not just a fundraising mechanism. It is validation. It tells the market that international partners are willing to attach real dollars to discovery work, even under heightened scrutiny.

Now add the AI angle. The source frames these companies as AI-driven drug-design firms, and the broader implication is straightforward: if AI can shorten the time from target selection to early candidate creation, licensing becomes more attractive because there is something concrete to negotiate. Even when deals are structured in stages, a stronger early technical package can pull more attention, more interest from large partners, and more competitive pressure across the sector.

But Washington’s growing scrutiny is the counterweight that keeps showing up in boardrooms. When US regulators increase scrutiny of Chinese biotech firms, the risk is not only compliance risk. It is also deal friction. Executives at multinationals have to think about how scrutiny could affect timelines, data handling, trial pathways, supply chains, or future expansions of existing collaborations. Yet the US attention has not stopped the licensing wave described by HSBC's Linda Shu. The implication for dealmakers is that scrutiny might be changing how deals are structured rather than whether they happen at all.

The other key detail executives will notice is the timeframe. The source highlights that deal value grew to US$75 billion in the first five months of 2026, up from zero before 2020. That jump suggests the market did not gradually inch upward over many years. Something shifted around the 2020 era, and then deal activity kept accelerating into the mid-2020s. Whether the trigger is AI adoption, cross-border partnership models, investor appetite, or a shift in pharma’s external innovation strategy, the effect is the same for current decision-makers: the licensing channel is now a mainstream way for global pharma to pursue innovation, and it is increasingly tied to Chinese discovery efforts.

For executives and boards, the second-order impact is competitive and strategic. If Chinese biotech out-licensing is reaching US$75 billion in just five months, multinational pharma companies that move slowly risk missing the best entry points into promising programs. At the same time, rushing without a compliance and risk plan could magnify exposure to scrutiny-related delays. That creates an uncomfortable balance: move fast enough to secure deals, but build governance and due diligence deep enough to withstand regulatory pressure.

The strategic stakes are bigger than any single deal term sheet. If licensing deal value can rise from zero before 2020 to US$75 billion in the first five months of 2026, the global deal landscape is changing in real time. Executives who treat cross-border AI drug discovery as a “watch this space” trend may wake up to a world where supply of innovation is being sourced and monetized differently, with China biotech playing a much larger role than many people were priced for earlier in the decade.